Somatogen's secret agents

Somatogen Inc.'s recent prospectus reveals that the company used unnamed drugs to treat mild to moderate gastrointestinal symptoms in its Phase Ib trial of rHb1.1 recombinant hemoglobin. The disclosure was bound to cause the curious to do some digging.

The company has declined to confirm or deny the use of specific agents because it is filing patent applications. "Even though the agents are commonly used, we're applying for patents for use of these agents in the setting where we're using them," said David Mason, vice president of clinical sciences at SMTG. The company has a U.S. patent filing ready to go out.